Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
DomainIg_I-set

KDR PTPRD MYBPC3

3.12e-03190293IPR013098
DomainI-set

KDR PTPRD MYBPC3

3.12e-03190293PF07679
DomainChannel_four-helix_dom

KCNB1 NALCN

3.52e-0357292IPR027359
Domain-

KCNB1 NALCN

3.52e-03572921.20.120.350
DomainIGc2

KDR PTPRD MYBPC3

5.64e-03235293SM00408
DomainIg_sub2

KDR PTPRD MYBPC3

5.64e-03235293IPR003598
DomainZnf_PHD-finger

KDM2A KAT6A

6.66e-0379292IPR019787
DomainPHD

KDM2A KAT6A

8.38e-0389292SM00249
DomainZnf_PHD

KDM2A KAT6A

8.75e-0391292IPR001965
DomainZF_PHD_2

KDM2A KAT6A

9.51e-0395292PS50016
DomainZF_PHD_1

KDM2A KAT6A

9.70e-0396292PS01359
DomainIon_trans_dom

KCNB1 NALCN

1.35e-02114292IPR005821
DomainIon_trans

KCNB1 NALCN

1.35e-02114292PF00520
Pubmed

The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.

MYOF KDM2A ANKLE2 TOP2A KAT6A AHNAK2

2.86e-0733229637433992
Pubmed

Myoferlin silencing inhibits VEGFR2-mediated proliferation of metastatic clear cell renal cell carcinoma.

MYOF KDR

6.71e-07229231477752
Pubmed

KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.

YY1AP1 KAT6A

6.71e-07229234808502
Pubmed

AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration.

MYOF AHNAK2

4.02e-06429217185750
Pubmed

Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function.

MYOF KDR

4.02e-06429217702744
Pubmed

New nomenclature for chromatin-modifying enzymes.

EHMT1 KDM2A KAT6A

1.48e-055729318022353
Pubmed

Homologs of genes expressed in Caenorhabditis elegans GABAergic neurons are also found in the developing mouse forebrain.

MYH8 CUX2 KAT6A

1.48e-055729321122108
Pubmed

A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.

EHMT1 MYOF KDM2A TRIP4 AHNAK2 SFXN3

2.52e-0572429636232890
Pubmed

Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.

EHMT1 MYOF KDM2A CUX2

3.57e-0522529412168954
Pubmed

Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.

MYOF OSBPL3 KAT6A SFXN3

8.68e-0528329418854154
Pubmed

Investigation of genetic susceptibility factors for human longevity - a targeted nonsynonymous SNP study.

EHMT1 KDR TOP2A KAT6A

1.28e-0431329420800603
Pubmed

HBO1 is required for H3K14 acetylation and normal transcriptional activity during embryonic development.

KDR KAT6A

1.83e-042429221149574
Pubmed

Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans.

KDR SFXN3

1.99e-042529219372376
Pubmed

Genomic analysis of gastrulation and organogenesis in the mouse.

KDR MYBPC3

2.15e-042629218061570
Pubmed

Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.

EHMT1 KDM2A MMP11 KCNB1 KAT6A

3.14e-0473029534857952
Pubmed

Integrated Transcriptome and Network Analysis Reveals Spatiotemporal Dynamics of Calvarial Suturogenesis.

MYH8 TOP2A

3.49e-043329232640236
Pubmed

Gfi1b regulates the level of Wnt/β-catenin signaling in hematopoietic stem cells and megakaryocytes.

EHMT1 KDM2A

3.70e-043429230894540
Pubmed

Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice.

EHMT1 MYH8

4.88e-043929224703692
Pubmed

Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays.

ASPSCR1 KCNB1 ADAP2

6.40e-0420329319953087
Pubmed

Identification of Jmjd3 as an Essential Epigenetic Regulator of Hox Gene Temporal Collinear Activation for Body Axial Patterning in Mice.

EHMT1 KDM2A

7.71e-044929234368113
InteractionMEX3A interactions

MYOF KDM2A ANKLE2 TOP2A KAT6A AHNAK2

1.51e-05384296int:MEX3A
Cytoband11q13.2

KDM2A CCDC87

4.09e-044729211q13.2
GeneFamilyBlood group antigens|CD molecules|I-set domain containing|Immunoglobulin like domain containing

KDR PTPRD MYBPC3

1.22e-03161243593
GeneFamilyPHD finger proteins

KDM2A KAT6A

6.30e-039024288
GeneFamilyFibronectin type III domain containing

PTPRD MYBPC3

1.89e-02160242555
GeneFamilyPleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing

OSBPL3 ADAP2

3.02e-02206242682
ToppCellTCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Adenocarcinoma_Mixed_Subtype-4|TCGA-Lung / Sample_Type by Project: Shred V9

MYOF KDR ADAP2 SFXN3

4.98e-061762940923b01137d6f9956ca815b41102c81e82624065
DrugCalycanthine [595-05-1]; Up 200; 11.6uM; MCF7; HT_HG-U133A

MYOF MMP11 KCNB1 KAT6A AHNAK2

4.18e-061932952764_UP
DrugAC1L2A1B

ST3GAL4 MMP11

3.28e-057292CID000017455
Drug2,4-diphenyl-1-butene

ST3GAL4 MMP11

5.61e-059292CID000519286
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

ADAP2 AHNAK2 SFXN3 CCDC87

7.86e-051812941471_UP
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

EHMT1 MYOF DCAF11 AHNAK2

8.55e-051852941022_UP
DrugMycophenolic acid [24280-93-1]; Up 200; 12.4uM; MCF7; HT_HG-U133A

ST3GAL4 APOBEC3C ADAP2 AHNAK2

8.55e-051852944137_UP
DrugEtodolac [41340-25-4]; Down 200; 14uM; PC3; HT_HG-U133A

MYOF KDM2A ASPSCR1 DCAF11

1.03e-041942942091_DN
DrugIopanoic acid [96-83-3]; Down 200; 7uM; MCF7; HT_HG-U133A

EHMT1 MYOF KAT6A ADAP2

1.03e-041942943527_DN
DrugHaloperidol [52-86-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A

EHMT1 MYOF KAT6A ADAP2

1.05e-041952941539_UP
DrugSB 202190; Down 200; 1uM; MCF7; HT_HG-U133A

EHMT1 MYOF HERC6 ADAP2

1.05e-041952946887_DN
DrugMethylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; MCF7; HT_HG-U133A

ASPSCR1 ST3GAL4 HERC6 SFXN3

1.07e-041962943333_DN
DrugNeomycin sulfate [1405-10-3]; Down 200; 4.2uM; MCF7; HT_HG-U133A

EHMT1 MYOF ADAP2 AHNAK2

1.07e-041962942229_DN
DrugMeropenem [96036-03-2]; Up 200; 10.4uM; MCF7; HT_HG-U133A

CUX2 KCNB1 OSBPL3 AHNAK2

1.07e-041962943564_UP
DrugBenfotiamine [22457-89-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A

MYOF DCAF11 MMP11 CCDC87

1.07e-041962943837_UP
DrugNorfloxacin [70458-96-7]; Down 200; 12.6uM; PC3; HT_HG-U133A

KDM2A ASPSCR1 ST3GAL4 DCAF11

1.07e-041962942090_DN
DrugProcainamide hydrochloride [614-39-1]; Up 200; 14.8uM; MCF7; HT_HG-U133A

MYOF PTPRD KCNB1 CCDC87

1.09e-041972942618_UP
Drug2-propylpentanoic acid; Down 200; 500uM; MCF7; HT_HG-U133A

MYOF ASPSCR1 DCAF11 ADAP2

1.09e-041972946999_DN
DrugRifampicin [13292-46-1]; Up 200; 4.8uM; MCF7; HT_HG-U133A

ST3GAL4 APOBEC3C ADAP2 AHNAK2

1.11e-041982944126_UP
Drug(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Down 200; 12.2uM; MCF7; HT_HG-U133A

KDM2A HERC6 KAT6A SFXN3

1.11e-041982945533_DN
DrugAntimycin A [1397-94-0]; Up 200; 7.2uM; PC3; HT_HG-U133A

ST3GAL4 MMP11 KCNB1 ADAP2

1.11e-041982945053_UP
DrugICI 182,780; Up 200; 1uM; MCF7; HT_HG-U133A

DCAF11 MMP11 ADAP2 MYBPC3

1.11e-041982946925_UP
DrugSulfamerazine [127-79-7]; Up 200; 15.2uM; PC3; HT_HG-U133A

EHMT1 DCAF11 MMP11 KCNB1

1.13e-041992943718_UP
DrugFluocinonide [356-12-7]; Up 200; 8uM; MCF7; HT_HG-U133A

MYOF ST3GAL4 KAT6A CCDC87

1.13e-041992943839_UP
DrugFolinic acid calcium salt [6035-45-6]; Up 200; 7.8uM; HL60; HT_HG-U133A

EHMT1 MYOF KDR ASPSCR1

1.13e-041992942579_UP
DrugBenzocaine [94-09-7]; Down 200; 24.2uM; HL60; HT_HG-U133A

MYOF KDM2A APOBEC3C OSBPL3

1.13e-041992942167_DN
DrugProcaine hydrochloride [51-05-8]; Up 200; 14.6uM; PC3; HT_HG-U133A

MYOF DCAF11 HERC6 MYBPC3

1.16e-042002946329_UP
DrugPrilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; MCF7; HT_HG-U133A

MYH8 MMP11 AHNAK2 CCDC87

1.16e-042002942314_UP
DrugC14561

ST3GAL4 MMP11

1.63e-0415292CID000177033
DrugIsoproterenol

KDR CUX2 PTPRD MMP11 KCNB1 AHNAK2 MYBPC3

2.27e-041016297ctd:D007545
DrugAC1L1FT2

ST3GAL4 MMP11

2.64e-0419292CID000003381
Drugsqualamine

KDR APOBEC3C

3.56e-0422292CID000072495
Drugmalathion

KDR ASPSCR1 MYBPC3

4.61e-04119293CID000004004
DrugCAS 83919-23-7

ST3GAL4 MMP11

5.00e-0426292CID000004240
DrugSp 6

ST3GAL4 MMP11

5.80e-0428292CID000146985
DrugAC1NRBPQ

MYH8 ST3GAL4 MYBPC3

6.94e-04137293CID005288569
DrugMG-262; Up 200; 0.1uM; PC3; HT_HG-U133A

KDM2A ANKLE2 OSBPL3

1.11e-031612937068_UP
DrugMG-262; Up 200; 0.1uM; PC3; HT_HG-U133A

KDM2A ANKLE2 OSBPL3

1.17e-031642937079_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ASPSCR1 ST3GAL4 HERC6

1.30e-031702935260_DN
DrugST-8

ST3GAL4 MMP11

1.31e-0342292CID005289411
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

KDM2A ASPSCR1 ST3GAL4

1.39e-031742935693_DN
DrugRifabutin [72559-06-9]; Up 200; 4.8uM; MCF7; HT_HG-U133A

KCNB1 AHNAK2 SFXN3

1.41e-031752933873_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

KCNB1 AHNAK2 SFXN3

1.45e-031772933395_UP
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; HL60; HT_HG-U133A

ASPSCR1 CUX2 HERC6

1.48e-031782936193_DN
DrugMG-262; Down 200; 0.1uM; PC3; HT_HG-U133A

ST3GAL4 TOP2A SFXN3

1.48e-031782937079_DN
Drugtrichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A

KCNB1 AHNAK2 CCDC87

1.50e-031792935903_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

KCNB1 AHNAK2 SFXN3

1.53e-031802936064_UP
DrugMethotrexate [59-05-2]; Down 200; 8.8uM; MCF7; HT_HG-U133A

KDM2A TOP2A ADAP2

1.55e-031812935419_DN
DrugZuclopenthixol hydrochloride [633-59-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A

ASPSCR1 AHNAK2 SFXN3

1.60e-031832934843_UP
DrugF0447-0125; Down 200; 10uM; PC3; HT_HG-U133A

MYOF ASPSCR1 AHNAK2

1.63e-031842936429_DN
DiseaseDistal arthrogryposis

MYH8 NALCN

3.34e-059292cv:C0265213
DiseaseAdenoid Cystic Carcinoma

ST3GAL4 TOP2A KAT6A

1.29e-04100293C0010606
DiseaseOsteochondrodysplasias

KDR SLC10A7

1.58e-0419292C0029422
DiseaseAdult Medulloblastoma

EHMT1 KAT6A

8.21e-0443292C0278876
DiseaseChildhood Medulloblastoma

EHMT1 KAT6A

8.21e-0443292C0278510
DiseaseMelanotic medulloblastoma

EHMT1 KAT6A

8.21e-0443292C1275668
DiseaseMedullomyoblastoma

EHMT1 KAT6A

8.21e-0443292C0205833
DiseaseDesmoplastic Medulloblastoma

EHMT1 KAT6A

8.21e-0443292C0751291
DiseaseMalignant neoplasm of salivary gland

ST3GAL4 TOP2A

8.99e-0445292C0220636
DiseaseSalivary Gland Neoplasms

ST3GAL4 TOP2A

9.81e-0447292C0036095
Diseasevital capacity

MIGA1 KDR KDM2A ASPSCR1 PTPRD ADAP2

1.11e-031236296EFO_0004312
DiseaseMedulloblastoma

EHMT1 KAT6A

1.11e-0350292C0025149
DiseaseIGF-1 measurement

ST3GAL4 CUX2 TOP2A MYBPC3

1.26e-03488294EFO_0004627
Diseasecancer (implicated_via_orthology)

KDR CUX2 TOP2A

2.27e-03268293DOID:162 (implicated_via_orthology)
DiseaseColorectal Neoplasms

KDR KDM2A PTPRD

2.50e-03277293C0009404

Protein segments in the cluster

PeptideGeneStartEntry
RKLWKTPPREKAGFL

ANKLE2

536

Q86XL3
KRSLGKVPKWLKLPA

ASPSCR1

536

Q9BZE9
EPFKPWKGLKTNFRL

APOBEC3C

166

Q9NRW3
KKPFHWLPSIGKKRE

CCDC87

261

Q9NVE4
KPWRKLTVKGKEPFI

CUX2

596

O14529
GPKQKEPFKKRWFAL

ADAP2

266

Q9NPF8
FVPPPKDWKISKNLK

LRRC69

306

Q6ZNQ3
IKDWLERKKPPFGAI

SLC10A7

191

Q0GE19
PWMKLFFKIKPLLKS

MYH8

831

P13535
QVPKKAWRKLKLPGD

DCAF11

411

Q8TEB1
WFPAKPKPEKKRYFL

HERC6

746

Q8IVU3
IHWKKRPGRKPGFKL

KAT6A

1161

Q92794
WPKRDKLKFPTRPKV

KDM2A

516

Q9Y2K7
SPKKWKFFKGPLNAI

KCNB1

251

Q14721
FLKRKGKTDSPWIKP

EHMT1

426

Q9H9B1
PPVQKGFLLKKRKWP

OSBPL3

51

Q9H4L5
PLKKSRGKFIKPWES

PTPRD

1146

P23468
KRGKKKGKILPWEPE

MIGA1

96

Q8NAN2
WKFDPVKVKALEGFP

MMP11

456

P24347
EKKDFLKRRPWLGAP

SFXN3

251

Q9BWM7
DKKRVRKGFWKQPPL

ST3GAL4

206

Q11206
ELPKKQEKAGWFRFP

AHNAK2

5686

Q8IVF2
LKLKPVADRFPKKAW

YY1AP1

436

Q9H869
AFKPIKKGKKRNPWS

TOP2A

1281

P11388
FPIKGNPKIWKLDSK

TRIP4

551

Q15650
KWEFPRDRLKLGKPL

KDR

826

P35968
LNLKLRPGEKKPGFW

NALCN

1071

Q8IZF0
KIKLKREFFLPPKGW

MYOF

891

Q9NZM1
ASLLKPPVVKWFKGK

MYBPC3

181

Q14896